Andy Blauvelt, EADV 2021: Switching from Dupilumab to Upadacitinib in Atopic Dermatitis
It was a pleasure to speak with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the recent open-label study investigating the efficacy and safety of switching from dupilumab to upadacitinib in the treatment of atopic dermatitis.
His presentation entitled ‘Efficacy and Safety of Switching from Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from an Open Label Extension Trial’ was given at the EADV 30th Congress, 29 Sep – 2 Oct.
- Could you give us a brief overview of dupilumab and upadacitinib, their mechanisms of action and their means of administration? (0:15)
- What is the rationale for switching from dupilumab to upadacitinib in the treatment of moderate-to-severe atopic dermatitis? (1:26)
- Could you tell us a little about the methodology of your clinical trial? (2:15)
- What were the findings of the open-label extension study and what are their clinical implications? (2:55)
- How likely is it in the future that upadacitinib will replace dupilumab as first-line treatment of moderate-to-severe atopic dermatitis? (4:23)
Disclosures: Dr Andy Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Vibliome.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Matthew Goodwin.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
Share this Video
Related Videos In Atopic Dermatitis
Amy Paller, Dermatology Meeting News 2023: The efficacy of dupilumab in children with atopic dermatitis
Dupilumab is a monoclonal antibody approved for use in patients with atopic dermatitis that is not well controlled with topical treatments, or who are unable to use topical treatments. It was a pleasure to talk with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children’s Hospital of Chicago, Chicago, IL, USA) about the […]
Amy Paller, Dermatology Meeting News 2023: Current treatment paradigm for atopic dermatitis in children
Atopic dermatitis is a chronic skin disorder causing inflammation, redness and irritation of the skin, and usually begins in childhood. touchIMMUNOLOGY caught up with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children’s Hospital of Chicago, Chicago, IL, USA), to discuss the current treatment paradigm for atopic dermatitis in children, and factors that […]
Melinda Gooderham, Dermatology Meeting News 2023: Abrocitinib efficacy in atopic dermatitis by baseline disease severity – findings from an interim analysis of JADE EXTEND
JADE-EXTEND (NCT03422822) is a phase 3 long-term extension study investigating the efficacy and safety of abrocitinib in atopic dermatitis. In this touchIMMUNOLOGY interview, we caught up with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, Canada) around her interim analysis of JADE-EXTEND, looking at efficacy by baseline disease severity. The abstract ‘Influence of Baseline Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!